NCT07118176View on ClinicalTrials.gov

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

September 6, 2026

Study Completion Date

September 7, 2027

Conditions
Anal CarcinomaBladder CarcinomaBreast CarcinomaCervical CarcinomaCholangiocarcinomaColorectal CarcinomaEsophageal CarcinomaGastric CarcinomaHead and Neck CarcinomaHematopoietic and Lymphatic System NeoplasmHepatocellular CarcinomaLung CarcinomaMalignant Adrenal Gland NeoplasmMalignant Brain NeoplasmMalignant Neoplasm of Unknown PrimaryMalignant Solid NeoplasmMalignant Testicular NeoplasmMalignant Uterine NeoplasmNeuroendocrine NeoplasmOvarian CarcinomaPancreatic CarcinomaPenile CarcinomaPleural CarcinomatosisPrimary Peritoneal CarcinomaProstate CarcinomaSalivary Gland CarcinomaSarcomaSkin CarcinomaSolitary Fibrous TumorThymus CarcinomaThyroid Gland CarcinomaThyroid Gland Medullary CarcinomaUrothelial CarcinomaVaginal Carcinoma
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Fludeoxyglucose F-18

Given IV

RADIATION

Gallium Ga 68 FAPi-46

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER